论文部分内容阅读
白细胞介素5参与介导嗜酸性粒细胞的趋化活化和存活,在哮喘患者,嗜酸性粒细胞的积聚与气道高反应性和炎性介质的产生相关。在这个多中心-随机-安慰剂对照的临床研究中,研究者试图明确使用mepolizumab (Mep)这种人化的单克隆白细胞介素5抗体能否改善哮喘患者症状评分,痰嗜酸性粒细胞和生活质量。研究对象年龄为18～55岁,肺功能FEV1大于50%但小于80%预测值,用吸入性类固醇及β受体激动剂治疗哮喘。参加者来自法国,德国,荷兰,英国和美国的55个中心,362例患者随机分为三组:MEP250毫克,
Interleukin 5 is involved in mediating the chemotactic activation and survival of eosinophils, and in asthmatics, the accumulation of eosinophils is associated with airway hyperresponsiveness and the production of inflammatory mediators. In this multicenter-randomized-placebo-controlled clinical study, the investigators sought to determine whether the use of mepolizumab (Mep), a humanized monoclonal IL-5, could improve symptom scores in asthma patients, sputum eosinophil and Quality of Life. The subjects were aged 18-55 years. Predictors of pulmonary function FEV1 were greater than 50% but less than 80%. Asthma was treated with inhaled steroids and beta-agonists. Participants were from 55 centers in France, Germany, the Netherlands, the United Kingdom and the United States. 362 patients were randomized into three groups: MEP 250 mg,